- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Agreement will speed drug approvals
New drugs will reach patients sooner as a result of a new agreement between the United States and the European Union.
New drugs will reach patients sooner as a result of a new agreement between the United States and the European Union.
The Mutual Recognition Act removes various regulatory barriers for a wide range of products, including pharmaceuticals.
The agreement was developed primarily by the U.S. Food and Drug Administration, the U.S. Department of Commerce and the European Commission, a governing office of the European Union.
According to the agreement, the United States and participating European countries will recognize each others' inspections of pharmaceutical manufacturing facilities. This agreement will reduce costs for governments and manufacturers and ultimately translate into fewer delays in the availability of new medicines.
Previously, inspectors from each jurisdiction had to inspect every factory where an imported drug was manufactured.
Awaiting cures
"At a time when patients everywhere are waiting for cures for AIDS, Alzheimer's, cancer and a host of other diseases, this agreement will help get new treatments to patients fast," said Alan Holmer, president of the Pharmaceutical Research and Manufacturers of America, in support of the cooperative effort.
"The money saved by avoiding duplication of effort can be used to increase research on cures for currently incurable diseases," Holmer said. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
